drugset
drugset / Trial / NCT02436486

Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men

NCT02436486 ↗

Phase 1 Completed 76 enrolled H. Lundbeck A/S
RandomizedCrossoverDouble-blindTreatment

Summary

To evaluate the effect of idalopirdine (120 and 360 mg) on cardiac repolarisation in healthy men.

Timeline

Start
2015-05
Primary completion
2015-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Idalopirdine Small molecule 120 mg Oral
Subject Idalopirdine Small molecule 360 mg Oral
Comparator Moxifloxacin Small molecule 400 mg Oral

Indications

No indication recorded.